J FW

Attorney Docket No.: 24852-501 CIP5

Express Mail Label No.: EV376271783US

Date of Deposit: September 13, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PLICANTS:

Bacopoulos et al.

CONFIRMATION NUMBER:

6072

SERIAL NUMBER:

10/665,079

EXAMINER:

Not Yet Assigned

FILING DATE:

September 16, 2003

ART UNIT:

1614

For:

METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page), in duplicate;
- 3. Cited References A21-A23 and C81-C82; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP5. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Dated: September 13, 2005

Ivor Elrifi, Reg. No. 39,529

Caryn DeHoratius, Reg. No. 45,881

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS, et al.

666 Third Avenue, 24<sup>th</sup> Floor New York, New York 10017

Phone: (212) 935-3000 Fax: (212) 983-3115 Express Mail Label No.: EV376271783US Attorney Docket No.: 24852-501 CIP5

Date of Deposit: September 13, 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CANTS: Bacopoulos et al. CONFIRMATION NUMBER: 6072

SERIAL NUMBER: 10/665,079 EXAMINER: Not Yet Assigned

FILING DATE: September 16, 2003 ART UNIT: 1614

FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed to be required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants: Bacopoulos et al. Attorney Docket No.: 24852-501 CIP5

U.S.S.N.: 10/665,079

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP5. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Dated: September 13, 2005

Ivor Elrifi, Reg. No. 39,529 Caryn DeHoratius, Reg. No. 45,881

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS, et al.

666 Third Avenue, 24<sup>th</sup> Floor New York, New York 10017

Phone: (212) 935-3000 Fax: (212) 983-3115

PAGE 1 of 1

/ Please type a plus sign (+) in this box +

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	10/665,079	
SUPPLEMENTAL	Filing Date	09/16/03	
INFORMATION DISCLOSURE	First Named Inventor	Bacopoulos	
STATEMENT BY APPLICANT	Group Art Unit	1614	
	Examiner Name	Not Yet Assigned	
(use as many sheets as necessary)	Attorney Docket Number	24852-501 CIP5	

U.S. PATENT DOCUMENTS							
Exam Initial s	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A21	RE38,506 E	04/20/04	Breslow, et al.	514	316	10/04/1991
	A22	2003/0082666	05/01/03	Kammer, et al.	435	18	07/02/2002
	A23	2003/0235588	12/25/03	Richon, et al.	424	146.1	02/14/2003

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Docum Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

NON PATENT LITERATURE DOCUMENTS			
Exam Initials Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
	C81	O'Connor et al. (2001). Journal of the American Society of Hematology 611a, Abstract No. 2562.	
	C82	Kelly, et al. (2003). Clinical Cancer Research 9:3578-3588.	

*a copy of this reference is not provided as it was	previously cited by or submitted to the office in a prior application, Serial No.
, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,
continuation-in-part, and divisional applications).	

	Date Considered
--	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.